Selected Gamma Aminobutyric Acid (GABA) esters may provide analgesia for some central pain conditions

Perspectives in Medicinal Chemistry

Volumn 2010, Issue 4, 2010, Pages 23-31

  Goldberg, Joel S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Central pain; GABA; GABA esters

Indexed keywords

3 GLUCOSYL 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID DEHYDROASCORBIC ACID ESTER; 4 AMINOBUTYRIC ACID DERIVATIVE; 4 AMINOBUTYRIC ACID DIETHYLAMINO ETHYL ESTER; 4 AMINOBUTYRIC ACID ESTER DERIVATIVE; 4 AMINOBUTYRIC ACID ETHYL ESTER; 4 AMINOBUTYRIC ACID GLUCOSE ESTER; 4 AMINOBUTYRIC ACID INOSITOL ESTER; BACLOFEN; BUTYL 4 AMINOBUTYRIC ACID; CHLOROPROCAINE; CHOLESTERYL 4 AMINOBUTYRIC ACID; DEXAMETHASONE 4 AMINOBUTYRIC ACID; ESTERASE; LEVODOPA; MONOAMINE; PERPHENAZINE 4 AMINOBUTYRIC ACID ESTER; PROCAINE; SEROTONIN; TETRACAINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; BLOOD BRAIN BARRIER; BLOOD PH; CEREBROSPINAL FLUID PH; CLINICAL TRIAL; CONSTIPATION; DEPLETION; DEPRESSION; DRUG ACCUMULATION; DRUG DEGRADATION; DRUG DESIGN; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG INDICATION; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROTOXICITY; NONHUMAN; PAIN; PARKINSON DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SPASTICITY; SYNAPTIC TRANSMISSION; UNSPECIFIED SIDE EFFECT;

EID: 77955538464     PISSN: None     EISSN: 1177391X     Source Type: Journal    
DOI: 10.4137/pmc.s5490     Document Type: Review

References (41)

1. Yokota T. Thalamic mechanism of pain: shell theory of thalamic nociception. Jpn J Physiol. 1989;39(3):335-48. Review.
2. Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg. 2008 Aug;22(4):508-19. Review.
3. Slonimski M, Abram SE, Zuniga RE. Intrathecal baclofen in pain management. Reg Anesth Pain Med. 2004 May-Jun;29(3):269-76. Review.
4. Taira T, Ochiai T, Goto S, Hori T. Fifteen year experience of intrathecal baclofen treatment in Japan. Acta Neurochir Suppl. 2006;99:61-3.
5. Taira T. Intrathecal administration of GABA agonists in the vegetative state. Prog Brain Res. 2009;177:317-28.
6. Taira T, Hori T. Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl. 2007;97(Pt 1):227-9.
7. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol. 2006;54:1-27. Review.
8. Hao JX, Xu XJ, Wiesenfeld-Hallin Z. Intrathecal gamma-aminobutyric acidB (GABAB) receptor antagonist CGP 35348 induces hypersensitivity to mechanical stimuli in the rat. Neurosci Lett. 1994 Dec 5;182(2): 299-302.
9. Meyerson BA. Neurosurgical approaches to pain treatment. Acta Anaesthesiol Scand. 2001 Oct;45(9):1108-13. Review.
10. Gamel-Didelon K, Corsi C, Pepeu G, Jung H, Gratzl M, Mayerhofer A. Neuroendocrinology. An autocrine role for pituitary GABA: activation of GABA-B receptors and regulation of growth hormone levels. 2002 Sep;76(3):170-7.
11. Lux-Lantos VA, Bianchi MS, Catalano PN, Libertun C. GABA(B) receptors in neuroendocrine regulation. Cell Mol Neurobiol. 2008 Sep;28(6):803-17. Epub 2008 Feb 9. Review.
12. Canavero S, Bonicalzi V. The neurochemistry of central pain: evidence from clinical studies, hypothesis and therapeutic implications. Pain. 1998 Feb;74(2-3):109-14. Review.
13. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol. 2006;54:1-27. Review.
14. Goudet C, Magnaghi V, Landry M, Nagy F, Gereau RW 4th, Pin JP. Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev. 2009 Apr;60(1):43-56. Epub 2008 Dec 25. Review.
15. Ghafoor VL, Epshteyn M, Carlson GH, Terhaar DM, Charry O, Phelps PK. Intrathecal drug therapy for long-term pain management. Am J Health Syst Pharm. 2007 Dec 1;64(23):2447-61.
16. Johnston GA. Medicinal chemistry and molecular pharmacology of GABA(C) receptors. Curr Top Med Chem. 2002 Aug;2(8):903-13. Review.
17. Krogsgaard-Larsen P, Frølund B, Frydenvang K. GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr Pharm Des. 2000 Aug;6(12):1193-209. Review.
18. Jasmin L, Wu MV, Ohara PT. GABA puts a stop to pain. Curr Drug Targets CNS Neurol Disord. 2004 Dec;3(6):487-505. Review.
19. Victor E. Shashoua, United States Patent 5,051,448, GABA esters and GABA analog esters, 1991 Sep 24.
20. Schnapp M, Mays KS, North WC. Intravenous 2-chloroprocaine in treatment of chronic pain. Anesth Analg. 1981 Nov;60(11):844-5.
21. Atack JR, Perry EK, Bonham JR, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fluid. J Neurochem. 1987 Jun;48(6):1845-50.
22. Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx. 2005 Jan;2(1):44-53. Review.
23. Bodor N. Targeting drugs to the brain by sequential metabolism. NIDA Res Monogr. 1995;147:1-32. Review.
24. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1): 35-58.
25. Krogsgaard-Larsen P, Frølund B, Frydenvang K. GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr Pharm Des. 2000 Aug;6(12):1193-209. Review.
26. van Heijst a, Visser BF, Maas AH. A micromethod for the determination or pH and PCO2 in human cerebrospinal fluid. Clin Chim Acta. 1961 Jul;6:589-90.
27. Biehl D, Shnider SM, Levinson G, Callender K. Placental transfer of lidocaine: effects of fetal acidosis. Anesthesiology. 1978 Jun;48(6):409-12.
28. Larson GM, Sullivan HW Jr. Omeprazole, a long-lasting inhibitor of gastric secretion. J Surg Res. 1984 May;36(5):503-7.
29. de Jong Ruldoph E. Local Anesthetics, Chapter 9 Uptake, Distribution, and Elimination, St. Louis, Mosby-Year Book, 1994.
30. Rephaeli A, Gil-Ad I, Aharoni A, et al. Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. J Med Chem. 2009 May 14;52(9):3010-7.
31. Matsuyama K, Yamashita C, Noda A, et al. Evaluation of isonicotinoylgamma- aminobutyric acid (GABA) and nicotinoyl-GABA as pro-drugs of GABA. Chem Pharm Bull (Tokyo). 1984 Oct;32(10):4089-95.
32. Sirviö J, Rakonczay Z, Hartikainen P, Kasa P, Riekkinen PJ. The molecular forms of acetylcholinesterase in cerebrospinal fluid of normal subjects- effect of aging. J Neural Transm Gen Sect. 1991;86(2):147-50.
33. Kambam JR, Horton B, Parris WC, Hyman SA, Berman ML, Sastry BV. Pseudocholinesterase activity in human cerebrospinal fluid. Anesth Analg. 1989 Apr;68(4):486-8.
34. Evans RT. Cholinesterase phenotyping: clinical aspects and laboratory applications. Crit Rev Clin Lab Sci. 1986;23(1):35-64. Review.
35. Nudelman A, Gil-Ad I, Shpaisman N, et al. A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. J Med Chem. 2008 May 8;51(9):2858-62.
36. Jacob JN, Hesse GW, Shashoua VE. gamma-Aminobutyric acid esters. 3. Synthesis, brain uptake, and pharmacological properties of C-18 glyceryl lipid esters of GABA with varying degree of unsaturation. J Med Chem. 1987 Sep;30(9):1573-6.
37. Carelli V, Liberatore F, Scipione L, et al. Synthesis and biological evaluation of GABA derivatives able to cross the blood-brain barrier in rats. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3765-9.
38. Private communication.
39. de Jong Ruldoph E. Local Anesthetics, Chapter 10 Biotransformation, St. Louis, Mosby-Year Book, 1994.
40. Illingworth DR, Glover J. The composition of lipids in cerebrospinal fluid of children and adults. J Neurochem. 1971 May;18(5):769-76.
41. Private communication.